"10.1371_journal.pone.0056703","plos one","2013-02-27T00:00:00Z","Linong Ji; Xiaolin Tong; Hongyuan Wang; Haoming Tian; Huimin Zhou; Lili Zhang; Qifu Li; Yizhong Wang; Hongmei Li; Min Liu; Hongjie Yang; Yanbin Gao; Yan Li; Quanmin Li; Xiaohui Guo; Gangyi Yang; Zhongai Zhang; Zhiguang Zhou; Guang Ning; Yingli Chen; Sanjoy Paul; the Evidence-Based Medical Research of Xiaoke Pill Study Group","Peking University Peoples Hospital, Beijing, China; China Academy of Chinese Medicial Sciences Guanganmen Hospital, Beijing, China; Peking University School of Public Health, Beijing China; Sichuan University West China Hospital, Chengdu, China; The First Hospital of Hebei Medical University, Shijiazhuang, China; The Third Affiliated Hospital of Peking University of Traditional Chinese and Western Medicine, Beijing, China; The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; The Central Hospital of China Aerospace Corporation, Beijing, China; China Meitan General Hospital, Beijing, China; The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, Guangzhou, China; Shanghai University of Traditional Chinese Medicine Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, China; Beijing University of Traditional Chinese Medicine Dongfang Hospital, Beijing, China; Zhongshan University Sun Yai-sen Memorial Hospital, Zhongshan, China; General Hospital of PLA Second Artillery, Beijing, China; Peking University First Hospital, Beijing, China; The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China; Nanjing Hospital of Traditional Chinese Medicine, Nanjing, China; The Second Xiangya Hospital of Central South University, Changsha, China; Shanghai Jiaotong University Ruijin Hospital, Shanghai, China; Queensland Clinical Trials and Biostatistics Centre, School of Population Health, University of Queensland, Queensland, Australia","Â¶ Investigators in Evidence-Based Medical Research of Xiaoke Pill Study are listed in Appendix S1.","The authors have declared that no competing interests exist. Several authors have received speaking honoraria from several pharmaceutical companies as follows: Dr. Ji reports receiving consulting and lecture fees from Eli Lilly, Bristol-Myers Squibb, Novartis, Novo Nordisk, Merck, Bayer, Takeda, Sanofi-Aventis, GlaxoSmithKline, Roche, Johnson & Johnson, boehingeringelheim, and Guangzhou Zhongyi Pharmaceutical, and grants from Guangzhou Zhongyi Pharmaceutical and Bayer. Dr. Q Li reports receiving consulting and lecture fees from Eli Lilly, Novo Nordisk, and Sanofi-Aventis. Dr. Tian reports receiving lecture fees from Bristol-Myers Squibb, Novo Nordisk, Bayer, and Sanofi-Aventis. Dr. Y. Li reports receiving consulting fees from Novartis, Novo Nordisk, and Sanofi-Aventis and lecture fees from Novo Nordisk and Sanofi-Aventis. Dr. Guo reports receiving consulting fees from Novartis, Sanofi-Aventis, and Guangzhou Zhongyi Pharmaceutical and lecture fees from Sanofi-Aventis, Guangzhou Zhongyi Pharmaceutical, and Novo Nordisk. Dr. Y. Gao reports receiving consulting fees from Novartis, Sanofi-Aventis, and Guangzhou Zhongyi Pharmaceutical and lecture fees from Sanofi-Aventis, Guangzhou Zhongyi Pharmaceutical, and Novo Nordisk. Dr. M. Liu reports receiving lecture fees from Eli Lilly, Novo Nordisk, and Bayer. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2013","02","Linong Ji","LJ",22,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA
